57
Participants
Start Date
November 30, 2006
Primary Completion Date
May 31, 2009
Study Completion Date
August 31, 2009
Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
Allergy Associates of the Palm Beaches, North Palm Beach
Optimed Research, LLC, Columbus
Rainbow Babies and Children's Hospital, Cleveland
Rush University Medical Center, Chicago
Pediatric Allergy Immunology Associates, Dallas
Allergy, Asthma and Immunology Clinic PA, Irving
1st Allergy and Clinical Research Center, Centennial
Mattel Children's Hospital of UCLA, Los Angeles
University of Toronto, Toronto
The Hospital for Sick Children, Toronto
Lead Sponsor
Collaborators (1)
OMRIX Biopharmaceuticals
INDUSTRY
FFF Enterprises
INDUSTRY